Difference between revisions of "Pentostatin (Nipent)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)" to "Chronic lymphocytic leukemia (CLL/SLL)")
m
Line 19: Line 19:
  
 
==Also known as==
 
==Also known as==
2'-deoxycoformycin or dCF.
+
*'''Generic names:''' 2'-deoxycoformycin, dCF
 +
*'''Brand name:''' Nipent
  
 
==References==
 
==References==
Line 25: Line 26:
  
 
[[Category:Drug index]]
 
[[Category:Drug index]]
[[Category:Chemotherapy]]
 
 
[[Category:Intravenous medications]]
 
[[Category:Intravenous medications]]
 
[[Category:Neutral chemotherapy]]
 
[[Category:Neutral chemotherapy]]

Revision as of 01:22, 30 November 2017

General information

Class/mechanism: Purine (adenosine) analog, inhibitor of adenosine deaminase (ADA), causes elevated intracellular levels of dATP, and inhibits ribonucleotide reductase, which interferes with DNA synthesis. Pentostatin can also inhibit RNA synthesis and has been observed to cause DNA damage. ADA enzymatic activity is greater in T-cell malignancies compared to B-cell malignancies. Exact mechanism of action in hairy cell leukemia is not fully understood.[1][2][3]
Route: IV
Extravasation: neutral

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 10/11/1991: Initial FDA approval

Also known as

  • Generic names: 2'-deoxycoformycin, dCF
  • Brand name: Nipent

References